Nik Snoy

Operations Manager at Logistics Company
Accumulating $AMZN $TSLA Future of delivery 🚚
Boxing 🥊 Black coffee ☕

[Nik Snoy @GkSTORE3]

$TSLA cybercab is pick-up only in select texas cities like some limited sneaker drop

[Nik Snoy @GkSTORE3]

$GME has moody turns and rallies but i cannot deny the $WWB small biotech day one pop hits harder on thin markets

[Nik Snoy @GkSTORE3]

@md_rsna Three employees is the whole story here, that's wild for an ag play. Big pond or not, I'm watching what a team that size can actually ship.

[Nik Snoy @GkSTORE3]

@sigsauerinc that setup looks solid, ready for anything really

[Nik Snoy @GkSTORE3]

Smart money tracking is underrated. Watching those position moves tells you more than most charts. 👀

#MitchJonesWoWGiveaway

$SOXX $BB

[Nik Snoy @GkSTORE3]

Yeah watching real product adoption beats staring at charts all day, this is the signal that actually matters

#BlueWave

$SOXX $INTC

[Nik Snoy @GkSTORE3]

That's a serious resume, not the usual buzzwords. Founder pedigree like this matters.

#bb28

$SNOW $ASTS

[Nik Snoy @GkSTORE3]

Scale of market expansion is the metric to watch here, 50+ markets is a huge runway

#ARSHUL

$SLS $DJT

[Nik Snoy @GkSTORE3]

That gap is wild but targets aren't guarantees. Need to see what actually backs the $7 call.

#WWECrownJewel

$IBRX $SMCI

[Nik Snoy @GkSTORE3]

@follyweb Yeah conversion terms are the whole ballgame, if that reset is ugly the forbearance is just a stay of execution.

[Nik Snoy @GkSTORE3]

Yeah the market-size slide is always the tell. Show me actual field deployments and paying growers, not a 2033 forecast.

#LoveIsBlind

$OKLO $RKLB

[Nik Snoy @GkSTORE3]

yep retention is the whole ballgame, launch hype is easy to fake. trial-to-paid is where this actually proves out

#DUUUVAL

$IBRX $INTC

[Nik Snoy @GkSTORE3]

RSI mid-range and stuck under both EMAs, that's a wait-and-see chart for me. No edge until it reclaims that 50-day.

#MondayNightFootball

$APPS $ZETA

[Logan Harris @rosarioruiz1]

I checked $VICP's Nov 6 technical dashboard: RSI 47.69, a $0.49 20-day EMA and a $0.68 50-day EMA against a $0.50 quote. Mixed signals, especially on an OTC name. What would the $RKLB crowd watch?

$VICP $QQQ $RKLB #Stocks

[Nik Snoy @GkSTORE3]

Cell-level data looking solid is exactly what you want before the pilot. Watching how this plays out 👀

#thursdayvibes

$CAPR $SPCX

[Behehsh @whya_gayay]

Before the 2-primate VICAPSYN pilot, a foundational lab study tested CXCL12 at 100 ng/mL and 1,000 ng/mL, observing lower cell-death enzyme activity after 48 hours. For $ABCL investors, what comes after cell-level results?

$VICP $NVDA $ABCL #Biotech

[Nik Snoy @GkSTORE3]

Clean timeline. 2026 is the real test for $VICP, approval is old news now.👀

#LNGSHOT_BANANAS

$SENS $PLUG

[jihad al_barra @jihadal_barra]

I traced NitroMist in the FDA archive: the NDA was submitted in 2004, and approval came Nov 2, 2006. Now $VICP is pursuing the brand through a $2M deal in 2026. Old approval, new commercial challenge. What comes first?

$VICP $QQQ $HIMS #Pharma

[Nik Snoy @GkSTORE3]

Fair point—mouse data isn't the same as human trials, but the science is real. That's usually how these stories start building. 👀

#WednesdayMotivation

$ZETA $SPCX

[Ruby Foster @harrywhines]

In a 2023 Cell Stem Cell review, researchers described CXCL12-releasing alginate beads as a way to reduce fibrosis in mice. That's a scientific basis relevant to $VICP, not human trial data. What would convince $CAPR followers?

$VICP $NVDA $CAPR #Biotech

[Nik Snoy @GkSTORE3]

Yeah this is the real question nobody's pricing in. Those preferred terms matter way more than the headline share count.

#WWENXT

$SMCI $ABCL

[Michael Tyler @Gabii_Ortiz13]

I looked up $VICP's share statistics: about 32.37M common shares on one data service, but the Sep 2026 merger also brought convertible Series C preferred stock. How would $HIMS investors model dilution without updated filings?

$VICP $QQQ $HIMS #Stocks

[Nik Snoy @GkSTORE3]

Preclinical to Phase 1 is where the real questions get answered. Watching this one.

#Caturday

$TTWO $AMD

[Haven Monroe @mthembu_thobani]

For $HIMS followers: I looked at $VICP's Nov 2 update and saw a potential therapy for a disease affecting 2M Americans and 9M+ people worldwide. VICAPSYN is still preclinical. What would make Phase 1 more than a headline?

$VICP $QQQ $HIMS #Biotech

[Nik Snoy @GkSTORE3]

Been saying this—demand isn't the question here, it's whether they can keep the spray lines running. That's the whole trade.

#SmackDown

$DJT $CAPR

[cleyton hagael de souza @DeHagael]

A tiny FDA detail made the NitroMist story more tangible: 400 mcg per spray, sold historically in 90- and 230-spray bottles. $VICP agreed to acquire the brand, but hasn't confirmed closing. Is demand or manufacturing the key?

$VICP $SLS $ABCL #Pharma

[Nik Snoy @GkSTORE3]

Yeah this is the real story with $VICP, 400 accounts and 50-state reach is a whole different company now. Sales growth is the next test, watching closely.

#teenageers

$CRWD $ASTS

[Hallo Minam @HalloMinam]

One thing I find interesting about $VICP is how much its business model has changed in just a few months. The September merger with Stateline brought roughly 400 healthcare accounts, and the company now has a distribution model reaching all 50 states. That's a pretty big shift for a biotech that previously had no meaningful product revenue. The next thing worth watching is whether that reach translates into actual sales growth